A key advisory panel on Tuesday recommended the Pfizer-BioNTech COVID-19 shots for emergency use in children ages 5 to 11, setting the stage for shots to become available to 28 million children by early November and fueling debate over the risks and rewards of vaccinating an age group that's accounted for 0.01% of COVID-19 deaths in America.
The Pfizer pediatric vaccine, shown as 91 percent effective for children 5 to 11, cleared an FDA advisory panel Tuesday. Gov. Whitmer is seeking to expedite shipment of the vaccine, which could be approved by next week.
A key advisory panel on Tuesday recommended the Pfizer-BioNTech COVID-19 shots for emergency use in children ages 5 to 11, setting the stage for shots to become available to 28 million children by early November and fueling debate over the risks and rewards of vaccinating an age group that's accounted for 0.01% of COVID-19 deaths in America.